Drugs / LY518674
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00374855 | Sep → Nov 2006 | hypertensive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00327002 | Jan → Sep 2006 | metabolic syndrome X | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00133380 | Jul 2005 → Sep 2006 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00116519 | Jul 2005 → Oct 2006 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY518674 | “PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension” NCT00374855 ↗2“OBJECTIVES: To examine the safety and efficacy of LY518674, a PPAR-alpha agonist.” PMID 17384435 ↗ Mar 2007 |
| Known as | KB-68984 | ChEMBL registry synonym — accepted as the source's own label CHEMBL424133 ↗ |
| Known as | LY-674 | ChEMBL registry synonym — accepted as the source's own label CHEMBL424133 ↗ |
| Action | Activate | “a PPAR-alpha agonist” PMID 17384435 ↗ Mar 2007 |
| Modality | Small molecule | — CHEMBL424133 ↗ |
| Target | PPARA | “a PPAR-alpha agonist” PMID 17384435 ↗ Mar 2007 |